Literature DB >> 23296250

Oesophageal cancer--an overview.

Michael Schweigert1, Attila Dubecz, Hubert J Stein.   

Abstract

Oesophageal carcinoma is one of the most virulent malignant diseases and a major cause of cancer-related deaths worldwide. Diagnosis and accuracy of pretreatment staging have substantially improved throughout the past three decades. Therapy is challenging and the optimal approach is still debated. Oesophagectomy is considered to be the procedure of choice in patients with operable oesophageal cancer. Endoscopic measures and limited surgical procedures provide an alternative in patients with early carcinomas confined to the oesophageal mucosa. Chemotherapy and radiotherapy or concurrent chemoradiotherapy are also frequently applied, either as definitive treatment or as neoadjuvant therapy within multimodal approaches. The question of whether multimodal treatment offers improved results has been the focus of many studies since the 1990s. Although results are discordant and even some meta-analyses remain inconclusive, it is now widely accepted that multimodal therapy leads to a modest survival benefit. The role of minimally invasive oesophagectomy is not yet defined. Endoscopic stent insertion, radiotherapy and other palliative measures provide relief of tumour-related symptoms in advanced, unresectable tumour stages.

Entities:  

Mesh:

Year:  2013        PMID: 23296250     DOI: 10.1038/nrgastro.2012.236

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  172 in total

1.  Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial.

Authors:  H Bergquist; U Wenger; E Johnsson; J Nyman; H Ejnell; E Hammerlid; L Lundell; M Ruth
Journal:  Dis Esophagus       Date:  2005       Impact factor: 3.429

2.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

3.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

4.  Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden.

Authors:  Kazem Zendehdel; Olof Nyrén; Annika Edberg; Weimin Ye
Journal:  Am J Gastroenterol       Date:  2011-01       Impact factor: 10.864

5.  Smoking, type of alcoholic beverage and squamous-cell oesophageal cancer in northern Italy.

Authors:  P Zambon; R Talamini; C La Vecchia; L Dal Maso; E Negri; S Tognazzo; L Simonato; S Franceschi
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

6.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

Review 7.  Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.

Authors:  Christophe Mariette; Guillaume Taillier; Isabelle Van Seuningen; Jean-Pierre Triboulet
Journal:  Ann Thorac Surg       Date:  2004-10       Impact factor: 4.330

8.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Staging investigations for oesophageal cancer: a meta-analysis.

Authors:  E P M van Vliet; M H Heijenbrok-Kal; M G M Hunink; E J Kuipers; P D Siersema
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

10.  Transhiatal robot-assisted esophagectomy.

Authors:  J Boone; I H M Borel Rinkes; R van Hillegersberg
Journal:  Surg Endosc       Date:  2008-02-23       Impact factor: 4.584

View more
  40 in total

1.  Recurrent oesophageal cancer complicated by tracheo-oesophageal fistula: improved palliation by means of parallel tracheal and oesophageal stenting.

Authors:  Michael Schweigert; Maria Posada-González; Attila Dubecz; Dietmar Ofner; Herbert Muschweck; Hubert J Stein
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-10-29

2.  Emergency oesophagectomy for oesophageal perforation after chemoradiotherapy for oesophageal cancer.

Authors:  M Schweigert; N Solymosi; A Dubecz; M Posada Gonzalez; R J Stadlhuber; D Ofner; H J Stein
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

3.  Dinner-to-bed time and post-dinner walk: new potential independent factors in esophageal cancer development.

Authors:  Qingxu Song; Hong Liu; Jianbo Wang; Yibin Jia; Yuan Liu; Nana Wang; Bingxu Tan; Shanghui Guan; Dianzheng An; Yufeng Cheng
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-16       Impact factor: 4.553

4.  RNA-seq reveals determinants of sensitivity to chemotherapy drugs in esophageal carcinoma cells.

Authors:  Li-Xin Yang; Bai-Ling Li; Xiao-Hong Liu; Yang Yuan; Chao-Jing Lu; Rui Chen; Jian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

5.  Postoperative complications do not affect long-term outcome in esophageal cancer patients.

Authors:  Kirsten Lindner; Mathias Fritz; Christina Haane; Norbert Senninger; Daniel Palmes; Richard Hummel
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

6.  Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis.

Authors:  Xu Zhang; Lingzhi Sun
Journal:  Mol Clin Oncol       Date:  2017-12-06

7.  Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer : Clinical outcome, dosimetry, and feasibility.

Authors:  Yue-Can Zeng; Shilpa Vyas; Quang Dang; Lindsay Schultz; Stephen R Bowen; Veena Shankaran; Farhood Farjah; Brant K Oelschlager; Smith Apisarnthanarax; Jing Zeng
Journal:  Strahlenther Onkol       Date:  2016-09-05       Impact factor: 3.621

8.  Intrinsic apoptotic pathway and G2/M cell cycle arrest involved in tubeimoside I-induced EC109 cell death.

Authors:  Yang Xu; Guanghui Wang; Quancheng Chen; Ting Lin; Zhiping Zeng; Qiang Luo; Jie Liu; Cuiling Sun
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

Review 9.  Personalized targeted therapy for esophageal squamous cell carcinoma.

Authors:  Xiaozheng Kang; Keneng Chen; Yicheng Li; Jianying Li; Thomas A D'Amico; Xiaoxin Chen
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

10.  IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.

Authors:  Y Qiao; C Zhang; A Li; D Wang; Z Luo; Y Ping; B Zhou; S Liu; H Li; D Yue; Z Zhang; X Chen; Z Shen; J Lian; Y Li; S Wang; F Li; L Huang; L Wang; B Zhang; J Yu; Z Qin; Y Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.